Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design (Q42640514)

4 November 2017

title

Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design (English)

1 reference

4 November 2017

1 reference

10

1 reference

4 November 2017

5

Terence A Ketter

1 reference

4 November 2017

6

Joseph R Calabrese

1 reference

4 November 2017

1

Andrew A Nierenberg

1 reference

4 November 2017

9

Edward S Friedman

1 reference

4 November 2017

7

Michael E Thase

1 reference

Noreen A Reilly-Harrington

4 November 2017

4

object named as

Noreen A Reilly-Harrington

1 reference

4 November 2017

12

Dan V Iosifescu

1 reference

4 November 2017

2

Louisa G Sylvia

1 reference

4 November 2017

Andrew C Leon

3

1 reference

4 November 2017

Charles L Bowden

8

1 reference

4 November 2017

Lena Novak

11

1 reference

4 November 2017

Litmus Study Group

13

1 reference

4 November 2017

publication date

23 November 2009

1 reference

4 November 2017

1 reference

4 November 2017

volume

6

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

637-648

1 reference

The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Suicide as an outcome for mental disorders. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Social and economic burden of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

The enduring psychosocial consequences of mania and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

How does work work for people with bipolar affective disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A review of bipolar disorder among adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Self-reported quality of life across mood states in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Suicide risk in bipolar disorder during treatment with lithium and divalproex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Mood stabilizer combinations: a review of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Psychotropic drug prescription patterns among patients with bipolar I disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Is polarity of recurrence related to serum lithium level in patients with bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

MINI International Neuropsychiatric Schedule: clinical utility and patient acceptance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Assessment of suicidal intention: The Scale for Suicide Ideation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Random-effects models for longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Novel drugs and therapeutic targets for severe mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Missing data in longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

Perceptions and Impact of Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509347399

21 January 2018

Identifiers

DOI

10.1177/1740774509347399

1 reference

4 November 2017

1 reference